{"schema_version":"secwatch.filing_event.v1","accession":"0001906324-22-000026","form_type":"8-K","ticker":"QDEL","cik":"0001906324","company_name":"QuidelOrtho Corp","filed_at":"2022-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.960546+00:00","generated_at":"2026-06-23T04:10:34.579686+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"QuidelOrtho reports preliminary Q3 2022 revenue $782-785M; COVID revenue ~$171M","bullets":["Total revenue expected $782M-$785M; non-COVID product revenue $611M-$614M.","COVID-19 product revenue ~$171M, including unanticipated government order and strong retail demand.","Strong performance in Transfusion Medicine and Sofia platform; Labs challenged by China and supply chain.","Full Q3 2022 financial results to be reported on November 2, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001906324-22-000026","json":"https://secwatch.observer/filing/0001906324-22-000026.json","markdown":"https://secwatch.observer/filing/0001906324-22-000026.md","text":"https://secwatch.observer/filing/0001906324-22-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1906324/000190632422000026/0001906324-22-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1906324/000190632422000026/qdel-20221012.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T04:10:34.579686+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}